Enveric Biosciences
ENVB
26 hedge funds and large institutions have $4.44M invested in Enveric Biosciences in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 1 closing their positions.
3,000% more capital inflows, than outflows
Capital inflows: $4.1M | Capital outflows: $132K
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
718% more call options, than puts
Call options by funds: $368K | Put options by funds: $45K
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
44% more funds holding
Funds holding: 18 → 26 (+8)
11.87% more ownership
Funds ownership: 10.46% → 22.33% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pura Vida Investments
New York
|
+$1.15M |
| 2 |
Ikarian Capital
Dallas,
Texas
|
+$618K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$618K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$422K |
| 5 |
AdvisorShares Investments
Bethesda,
Maryland
|
+$408K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$56.2K |
| 2 |
Scotia Capital
Toronto,
Ontario, Canada
|
-$42.2K |
| 3 |
Squarepoint
New York
|
-$27K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$7K |
ENVB Hedge Fund Activity: Q4 2021 in Review
26 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2021, worth a combined $4.44M — down 4.2% from $4.64M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ENVB positions and 1 closed out — a net gain of 8 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $1.15M. The largest seller was Integrated Wealth Concepts, cutting an estimated $56.2K.
- 26 institutional investors held Enveric Biosciences (ENVB) as of Q4 2021, up from 18 in Q3 2021.
- Funds reported $4.44M of Enveric Biosciences stock for Q4 2021, down 4.2% quarter-over-quarter.
- 9 funds opened new Enveric Biosciences positions in Q4 2021 and 1 closed out, a net change of +8 holders.
- The largest Enveric Biosciences buyer in Q4 2021 was Pura Vida Investments, an estimated $1.15M added.
- The largest Enveric Biosciences seller in Q4 2021 was Integrated Wealth Concepts, an estimated $56.2K sold.
Based on aggregated 13F filings for Q4 2021.